Closely watched hedge fund manager Kyle Bass said Thursday that oil prices could rise "well north of $100" in 2022 as a lack of investment in the hydrocarbon industry meets a ...
Keep Reading →
January 14 - Hedge Funds, Insider Trading - Comments
The life sciences specialist’s hedge fund is down significantly this year — and its recently merged SPAC is also underwater.
Keep Reading →
July 26 - Hedge Funds, Insider Trading - Comments
Hedge fund manager Dan Niles told CNBC on Wednesday he likes shares of Magna International as an attractively priced way to get exposure to the buzzy electric vehicle market.
Keep Reading →
March 11 - Hedge Funds, Insider Trading - Comments
Sears Holdings Corp. Chairman Eddie Lampert won the support of the U.S.
Keep Reading →
February 7 - Hedge Funds, Insider Trading - Comments
Brevan Howard Asset Management is raising money for a new macro hedge fund managed by long-time trader Minal Bathwal, according to people with knowledge of the matter.
Keep Reading →
April 10 - Hedge Funds, Insider Trading - Comments
The last time we checked in with Joseph Edelman, the founder, chief executive and portfolio manager of Perceptive Advisors and its hedge fund, Perceptive Life Sciences, he was...
Keep Reading →
March 30 - Hedge Funds, Insider Trading - Comments
With the stock market having been battered in recent days and fears that a large correction may be starting to pick up steam becoming more pronounced, investors are now in a position...
Keep Reading →
February 5 - Hedge Funds, Insider Trading, Market Movers, News - Comments
Joseph Edelman's Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being invested in healthcare stocks.
Keep Reading →
November 8 - Hedge Funds, News - Comments
With the latest round of 13F filings gathering pace, hedge fund managers are busy preparing to deluge us with the contents of their portfolios, which powers our market-beating...
Keep Reading →
October 30 - Hedge Funds, News - Comments
Biotech Guru Joseph Edelman's Perceptive Advisors is known for its long-short investment approach that focuses on biotech stocks.
Keep Reading →
June 25 - Hedge Funds, News - Comments
The health care sector has appreciated by nearly 30% over the past year. We decided to take a look at three companies that two health care-focused funds, namely James A.
Keep Reading →
June 24 - Hedge Funds, News - Comments
Andreas Halvorsen’s Viking Global recently increased its exposure to Kansas City Southern (NYSE:KSU) by 1.3 million shares. According to the 13G Form filed with the U.S.
Keep Reading →
February 6 - Hedge Funds, News - Comments
Roberto Mignone’s Bridger Management has amassed a 5.5% stake in Arrowhead Research Corp (NASDAQ:ARWR) according to a 13G filing with the Securities and Exchange Commission ...
Keep Reading →
January 26 - Hedge Funds, News - Comments
Jeremy Green's Redmile Group has also reduced its stake in Amicus Therapeutics, Inc.
Keep Reading →
October 9 - Hedge Funds, News - Comments
Hal Mintz, the manager of Sabby Capital, believes StemCells Inc (NASDAQ:STEM) is a good investment and has opened a position for his fund.
Keep Reading →
July 17 - Hedge Funds, News - Comments
In a new filing with the Securities and Exchange Commission, James E. Flynn of Deerfield Management, has revealed a 6.05% stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI).
Keep Reading →
July 7 - Hedge Funds, News - Comments
Perceptive Advisors, managed by Joseph Edelman, is bullish on Amicus Therapeutics Inc. (NASDAQ:FOLD). In a new filing with the U.S.
Keep Reading →
July 2 - Hedge Funds, News - Comments
According to our research, stocks bought by insiders demonstrate a small outperformance effect, which seems logical given the fact that insiders are the most knowledgeable about...
Keep Reading →
April 4 - Hedge Funds, Insider Trading, News - Comments
HSBC Hedge Weekly, in its issue Nr. 48, has published a list of the best hedge fund returns.
Keep Reading →
December 18 - Hedge Funds, News - Comments
In a disclosure of its holdings, Joseph Edelman's Perceptive Advisors made public that it currently owns 6.57 million shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) last week...
Keep Reading →
November 18 - Hedge Funds, News - Comments
Joseph Edelman's fund Perceptive Advisors continues its bullish streak on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) disclosing increasing its position to over 6.57 million shares...
Keep Reading →
November 12 - Hedge Funds, News - Comments
Joseph Edelman's fund, Perceptive Advisors, in a new filing reported increasing its position in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) again, after disclosing a buy of around...
Keep Reading →
November 6 - Hedge Funds, News - Comments
Hedge fund Perceptive Advisors, founded and managed by Joseph Edelman, increased its position in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) by some 360,700 shares, to a total ...
Keep Reading →
November 4 - Hedge Funds, News - Comments
In the 21st century investor’s toolkit, there are dozens of indicators shareholders can use to analyze publicly traded companies.
Keep Reading →
September 17 - News - Comments
Now, according to many of your fellow readers, hedge funds are viewed as delayed, old investment tools of a forgotten age.
Keep Reading →
September 6 - News - Comments
To the average investor, there are dozens of methods investors can use to track publicly traded companies. Two of the best are hedge fund and insider trading sentiment.
Keep Reading →
September 4 - News - Comments
In the financial world, there are dozens of indicators investors can use to track publicly traded companies. Two of the best are hedge fund and insider trading movement.
Keep Reading →
September 4 - News - Comments
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Keep Reading →
August 30 - News - Comments
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Keep Reading →
August 30 - News - Comments
In today’s marketplace, there are tons of gauges market participants can use to track their holdings.
Keep Reading →
August 28 - News - Comments
To the average investor, there are dozens of gauges market participants can use to watch publicly traded companies.
Keep Reading →
August 26 - News - Comments
If you were to ask many of your peers, hedge funds are assumed to be overrated, outdated financial vehicles of a forgotten age.
Keep Reading →
August 22 - News - Comments
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the right investment to pursue these days? Hedge funds are taking a bullish view.
Keep Reading →
August 6 - News - Comments
To most shareholders, hedge funds are perceived as slow, outdated investment vehicles of yesteryear.
Keep Reading →
June 27 - News - Comments
Is AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) a first-rate investment today? Hedge funds are getting less optimistic.
Keep Reading →
June 26 - News - Comments
Pacific Biosciences of California (NASDAQ:PACB) was in 7 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 19 - News - Comments
In today’s marketplace, there are plenty of indicators market participants can use to track publicly traded companies.
Keep Reading →
June 17 - News - Comments
The list of the stocks with a high level of short interest is filled with many names investors should expect, while others may come as a surprise.
Keep Reading →
September 20 - Lists - Comments
